As leaders in hematologic oncology, stem cell, and bone marrow transplantation and immunotherapy, Duke Cancer Institute’s Hematologic Malignancies and Cellular Therapy (HMCT) disease group is internationally recognized for its novel approaches to treating leukemia, lymphoma, myeloma, and other life-threatening blood-related cancers.
We promote health and improve lives by preventing, diagnosing, and treating blood cancers through integrated, innovative, and holistic patient care, education, and research. We offer a broad selection of treatment options, including access to national and investigator-initiated clinical trials.
jacob.keller@duke.edu
919-660-3233
gabriel.alcantara@duke.edu
919-668-2121
quinna.marshburn@duke.edu
919-668-2556
Chief of Hematologic Malignancies and Cellular Therapy
Professor of Medicine
Stephanie Clune
Professor of Medicine
Assistant Professor of Medicine
Associate Professor of Medicine
Kimberly Smith
Professor of Medicine
Associate Professor of Medicine
Professor of Radiation Oncology
Associate Professor of Medicine
Assistant Professor of Medicine
Assistant Professor of Medicine
Jennifer Snyder
Associate Professor of Medicine
Amy Tammenga
Guiyun Zhou
Professor of Medicine
Professor of Medicine
Professor of Medicine
Professor of Medicine
Associate Professor of Medicine
Assistant Professor of Medicine
Associate Professor of Medicine
Assistant Professor of Medicine
Taylor Addis
Professor of Medicine
Professor of Medicine
Professor of Medicine
Melissa Martin
Emily Sellars
Scott Winkel
Professor of Medicine
Leighanne Hartman
Therese Hennig
Professor of Medicine
Professor of Medicine
Professor of Medicine
Brittany Matthews
Kerry Minor
Chief of Hematologic Malignancies and Cellular Therapy
Adjunct Associate Professor of Medicine
Kristi Wiggins
Yun-Hua Chiang
Instructor in the Department of Medicine
Allison Pereklita
The Duke Hematologic Malignancies & Cellular Therapy research program conducts basic, translational, and clinical research. The overall goal is to improve outcomes for patients with hematologic malignancies. We strive to build on and extend the current knowledge in the fields of leukemia, lymphoma, myeloma, hematopoietic cell transplantation, and immunotherapy, and to develop and implement novel strategies for improving therapeutic results in these patients through a collaborative and integrated approach involving all the investigators in the program.
Our research program can be broadly divided into the following research areas:
As a complement to our research efforts, there is also a robust clinical trials office with over 100 active clinical trials specific to hematologic malignancies and transplantation. These range from phase I “first in humans” to randomized phase III studies.
These trials range from securely storing your medical information in an outcomes-reporting registry, to sample repositories, and to national clinical trials and investigator-initiated trials designed to prevent, detect, or treat your underlying disease with the most advanced treatment methods.
Your participation may help you and others in the future.
Some of these trials are only offered at the Duke Cancer Institute. As a result, we offer a broad selection of treatment options to our patients, including some who are not considered candidates for treatment elsewhere. Your participation in a clinical trial may help you and others in the future.
